Comparison of comprehensive evaluation for dorzagliatin,metformin and linagliptin
Objective To conduct a comprehensive clinical evaluation of dorzagliatin,metformin and linagliptin to provide a basis for the selection of drugs in medical institutions.Methods Based on the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions(Second Edition),the drugs were scored in terms of pharmacological properties,effectiveness,safety,economy and other attributes,and recommendations were made based on the scoring results.Results The final scores of dorzagliatin,metformin and linagliptin were 77.0,72.3 and 76.2 respectively,and all of them were strongly recommended to be entered into the purchasing catalog of medical institutions or retained for use.The three drugs are oral hypoglycemic agents and each has its own advantages in the treatment of type 2 diabetes mellitus.Metformin is a classical drug and is recommended by the first class in many guidelines.As a new drug,dorzagliatin has advantages in glucose-lowering effect and safety,and it can improve patients'β-cell function while lowering glucose.Linagliptin is recommended as a drug to protect pancreatic β-cell function,and there is no need to adjust the dosage of the drug according to the patients'liver and kidney function.Conclusion Dorzagliatin,metformin and linagliptin have their own advantages in different attributes,and this drug selection can provide an evidence-based basis for medical institutions.
NETL
NSTL
万方数据
